179 related articles for article (PubMed ID: 16996663)
1. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.
Earnhart CG; Buckles EL; Marconi RT
Vaccine; 2007 Jan; 25(3):466-80. PubMed ID: 16996663
[TBL] [Abstract][Full Text] [Related]
2. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences.
Earnhart CG; Marconi RT
Hum Vaccin; 2007; 3(6):281-9. PubMed ID: 17921702
[TBL] [Abstract][Full Text] [Related]
3. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
Lovrich SD; Jobe DA; Schell RF; Callister SM
Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
[TBL] [Abstract][Full Text] [Related]
4. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
[TBL] [Abstract][Full Text] [Related]
5. Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development.
Buckles EL; Earnhart CG; Marconi RT
Clin Vaccine Immunol; 2006 Oct; 13(10):1162-5. PubMed ID: 17028218
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.
Earnhart CG; Buckles EL; Dumler JS; Marconi RT
Infect Immun; 2005 Dec; 73(12):7869-77. PubMed ID: 16299277
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
8. Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.
Earnhart CG; Marconi RT
Vaccine; 2007 Apr; 25(17):3419-27. PubMed ID: 17239505
[TBL] [Abstract][Full Text] [Related]
9. OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine.
Earnhart CG; Marconi RT
Clin Vaccine Immunol; 2007 May; 14(5):628-34. PubMed ID: 17360854
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
11. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
12. Development and optimization of OspC chimeritope vaccinogens for Lyme disease.
Izac JR; O'Bier NS; Oliver LD; Camire AC; Earnhart CG; LeBlanc Rhodes DV; Young BF; Parnham SR; Davies C; Marconi RT
Vaccine; 2020 Feb; 38(8):1915-1924. PubMed ID: 31959423
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.
Izac JR; Camire AC; Earnhart CG; Embers ME; Funk RA; Breitschwerdt EB; Marconi RT
Vaccine; 2019 Apr; 37(17):2401-2407. PubMed ID: 30922701
[TBL] [Abstract][Full Text] [Related]
14. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
15. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease.
Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM
Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a unique borreliacidal epitope on the outer surface protein C of Borrelia burgdorferi.
Yang X; Li Y; Dunn JJ; Luft BJ
FEMS Immunol Med Microbiol; 2006 Oct; 48(1):64-74. PubMed ID: 16965353
[TBL] [Abstract][Full Text] [Related]
17. Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development.
Oliver LD; Earnhart CG; Virginia-Rhodes D; Theisen M; Marconi RT
Vet J; 2016 Dec; 218():27-33. PubMed ID: 27938705
[TBL] [Abstract][Full Text] [Related]
18. OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands.
Pal U; Yang X; Chen M; Bockenstedt LK; Anderson JF; Flavell RA; Norgard MV; Fikrig E
J Clin Invest; 2004 Jan; 113(2):220-30. PubMed ID: 14722614
[TBL] [Abstract][Full Text] [Related]
19. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
20. Approaches toward the directed design of a vaccine against Borrelia burgdorferi.
Luft BJ; Dunn JJ; Lawson CL
J Infect Dis; 2002 Feb; 185 Suppl 1():S46-51. PubMed ID: 11865439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
